Market Overview

Bristol Myers Squibb Says Was Informed By FDA That Its Review Of The Biologics License Application For Lisocabtagene Maraleucel Will Not Be Completed By Nov. 16 PDUFA Date; FDA Was Unable To Conduct Inspection Due To COVID-19 Travel Restrictions

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

 

Related Articles (BMY)

Posted-In: Biotech News FDA General